EvoEnzyme is a spin-off from CSIC, Spain, which focuses its activities on the commercialization of ligninolytic enzymes engineered by directed evolution for the pharma and industrial sectors, together with the development of directed evolution projects.
EvoEnzyme has just been funded after over 15 years of research at the Miguel Alcalde group, whose more relevant findings have been transferred to the company.
With an ensemble of top-notch technologies, EvoEnzyme offers a variety of methods for library creation and screening aimed at designing customized biocatalysts.
The company has a wide portfolio of mutant libraries, including peroxygenases for the pharma industry and chemicals as well as laccases and peroxidases for the long-pursued lignocellulose biorefineries.
Company Details
- Employees
- 18
- Founded
- -
- Address
- C/ Faraday 7, Madrid,madrid 28049,spain
- in****@****yme.com
- Industry
- Biotechnology
- Website
- evoenzyme.com
- Keywords
- biotecnologia, ingenieria de enzimas, enzimas, enzimas ligninoliticas, evolucion dirigida, biotech, CSIC, Instituto de Catalisis, Premio Nobel de Quimica 2018.
- HQ
- Madrid, Madrid
Evoenzyme Questions
Evoenzyme's website is evoenzyme.com
Evoenzyme's LinkedIn profile is https://es.linkedin.com/company/evoenzyme
Evoenzyme has
18 employees.
View email and phone details for 18
employees at Evoenzyme.
Evoenzyme's industry is
Biotechnology
Evoenzyme's top competitors are
Bioassays,
Perseo Biotechnology S.l.,
Biohope,
Abalos Therapeutics Gmbh,
W-Biocat,
Bioprocesia,
Canvax,
Numaferm,
Priavoid Gmbh,
Navigo Proteins Gmbh.
Evoenzyme's support email address is info@envoenzyme.com
Evoenzyme's categories are Biotechnology
Evoenzyme's founding year is 2019
